Efaproxiral sodium

"目录号: HY-13619A

Others-

Efaproxiral钠是一种血红蛋白 (Hb) 合成变构调节剂, 降低血红蛋白氧 (O2) 的结合亲和力。

Others

相关产品

SBE-β-CD-MPTP hydrochloride-Cyclosporin A-Etomoxir-Auranofin-GKT137831-Ceruletide-Acetylcysteine-JC-1-BPTES-Brassinolide-FCCP-IPTG-MTT-RSL3 1S,3R--

生物活性

Description

Efaproxiral sodium is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy.in vitro: Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Efaproxiral can enhance the oxygenation of hypoxic tumours and function as a radiation sensitiser, increasing the effectiveness of RT.

Clinical Trial

NCT00083304

Spectrum Pharmaceuticals, Inc

Breast Cancer-Metastases

February 2004

Phase 3

NCT00005887

Spectrum Pharmaceuticals, Inc

Metastatic Cancer

February 2000

Phase 3

NCT00005855

New Approaches to Brain Tumor Therapy Consortium-National Cancer Institute (NCI)

Brain and Central Nervous System Tumors

July 2000

Phase 1-Phase 2

NCT00055887

Spectrum Pharmaceuticals, Inc

Lung Cancer

November 2002

Phase 3

NCT00004202

Spectrum Pharmaceuticals, Inc

Lung Cancer

October 1998

Phase 2

View MoreCollapse

References

[1].Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94(12):1777-1784.